Analysts and calls -- SG Cowen | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Analysts and calls -- SG Cowen

An SI Board Since October 2002

Posts	SubjectMarks	Bans
3	6	0

Emcee: Icebrg	Type: Unmoderated

Introduction Compact

2002-10-10
Genentech downgraded at SG Cowen (DNA) 31.88: SG Cowen downgrades to MKT PERFORM from Outperform due to a lack of significant catalysts until mid-2003; says total product sales continue to decelerate, and with a dearth of near-term new product launches, an aging Rituxan will continue to be the sole driver of product sales growthfor the next 12-18 months.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
3	Cephalon "strong buy" Thursday, July 03, 2003 10:39:00 AM ET SG Cowen	Icebrg	-	7/4/2003
2	State subpoenas files about SG Cowen analyst's firing Ex-staffer says he so	Icebrg	-	11/7/2002
1	I think Genentech and other companies should rate their analysts. Perhaps Genen	Harold Engstrom	-	10/10/2002

Go to reply# or date (mm/dd/yy):